Keyword Suggestion
Domain Informations
Orladeyo.com lookup results from whois.godaddy.com server:
- Domain created: 2018-02-10T21:45:03Z
- Domain updated: 2024-02-11T17:00:52Z
- Domain expires: 2025-02-10T21:45:03Z 0 Years, 95 Days left
- Website age: 6 Years, 270 Days
- Registrar Domain ID: 2225817643_DOMAIN_COM-VRSN
- Registrar Url: http://www.godaddy.com
- Registrar WHOIS Server: whois.godaddy.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: 480-624-2505
- Name server:
- KIP.NS.CLOUDFLARE.COM
- LANA.NS.CLOUDFLARE.COM
Network
- inetnum : 104.16.0.0 - 104.31.255.255
- name : CLOUDFLARENET
- handle : NET-104-16-0-0-1
- status : Direct Allocation
- created : 2010-07-09
- changed : 2021-07-01
- desc : All Cloudflare abuse reporting can be done via https://www.cloudflare.com/abuse,Geofeed: https://api.cloudflare.com/local-ip-ranges.csv
Owner
- organization : Cloudflare, Inc.
- handle : CLOUD14
- address : Array,San Francisco,CA,94107,US
Abuse
- handle : ABUSE2916-ARIN
- name : Abuse
- phone : +1-650-319-8930
- email : [email protected]
Technical support
- handle : ADMIN2521-ARIN
- name : Admin
- phone : +1-650-319-8930
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 104.21.36.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Site Inspections
Port Scanner (IP: 104.21.36.10)
Spam Check (IP: 104.21.36.10)
Recent Searched Sites
› Bjdaniels.com (7 seconds ago) / US
› Fastcapital360.com (0 seconds ago) / US
› Rosannapansino.com (29 seconds ago) / CA
› Irish-supply.com (1 seconds ago) / CA
› Yoojo.fr (5 seconds ago) / IE
› Talonjapan.com (14 seconds ago) / US
› Aqua-amore.com (8 seconds ago) / US
› Thessaliatv.gr (22 seconds ago) / US
› Yogurtjewel3.bravejournal.net (5 seconds ago) / US
› Orladeyo.com (0 seconds ago) / US
› Kastner-oehler.at (7 seconds ago) / AT
› Bookswagon.com (5 seconds ago) / IN
› Burbuja.info (4 seconds ago) / US
› Valleymetro.org (9 seconds ago) / US
› Clasificadosvanguardia.com (6 seconds ago) / NL
› Staylive.io (16 seconds ago) / US
› 95724063.007swz.com (0 seconds ago) / CN
› Dft.go.th (2 seconds ago) / TH
› Legend-footwear.com (6 seconds ago) / CA
› Pleanala.ie (7 seconds ago) / US
Websites Listing
We found Websites Listing below when search with orladeyo.com on Search Engine
Official Site for HAE Patients | ORLADEYO® (berotralstat)
If you change your mobile device number, you agree to promptly contact us at [email protected] so we can update our records and avoid having text messages inadvertently sent to an unintended recipient; Once enrolled in the Program, participants will receive approximately 30 text messages each month ; There is no fee payable to BioCryst to receive text messages; …
Orladeyo.comSign Up for Updates | ORLADEYO® (berotralstat)
If you change your mobile device number, you agree to promptly contact us at [email protected] so we can update our records and avoid having text messages inadvertently sent to an unintended recipient; Once enrolled in the Program, participants will receive approximately 30 text messages each month ; There is no fee payable to BioCryst to receive text messages; …
Orladeyo.comSpeak With a Representative | ORLADEYO® (berotralstat)
Email* NPI number (10 digits) ... ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring …
Orladeyohcp.comJoin our Mentor Program | ORLADEYO® (berotralstat)
Email the completed consent form to [email protected] or fax it to 1-844-336-7693. We will identify an appropriate mentor. Empower Patient Services will introduce you to each other . All conversations will then be arranged by you and your mentor a. For additional information, contact Empower Patient Services. Call 1-866-5-EMPOWER (1-866-536-7693) Monday – Friday 8:00 …
Orladeyo.comPatient Tools and Resources | ORLADEYO® (berotralstat)
For questions about ORLADEYO, please contact your healthcare provider or an Empower Patient Services care coordinator at 1-866-5-EMPOWER (1-866-536-7693) The Program is intended as a helpful reminder but does not constitute medical advice. You agree that the Program, including the content of the messages sent to you by it, are the property of ...
Orladeyo.comHow to Prescribe | ORLADEYO® (berotralstat)
With over 1000 prescriptions since launch, ORLADEYO is the fastest-growing therapy in hereditary angioedema (HAE). 1 Start your next patient in just 3 steps. Download the start form and fill it out. Download form. Once complete, fax or email the start form to Empower Patient Services. Fax: 1-844-336-7693. Email: [email protected].
Orladeyohcp.comOfficial Site for Physicians | ORLADEYO® (berotralstat)
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …
Orladeyohcp.comBenefits of Attack Prevention | ORLADEYO® (berotralstat)
By agreeing to the ORLADEYO ... and use of, this Program may include your mobile device number and/or email address and related carrier information, and will be used to provide dosing reminders and relevant updates and alerts. You may also receive additional educational, marketing communications, and promotional information about BioCryst, Empower Patient …
Orladeyo.comOrladeyo May Help Control Attacks in Patients With Normal ...
2022-02-17 · Orladeyo (berotralstat), an approved therapy for preventing swelling attacks in hereditary angiodema (HAE), was effective at controlling attacks in an HAE patient with normal C1 inhibitor activity, a case study reported.. The clinician said this oral therapy may be particularly suitable for patients who have a needle phobia and, as a result, may refuse treatment with …
Angioedemanews.comorladeyoeventshcp.com - BioCryst
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …
Orladeyoeventshcp.comOrladeyo Set to Launch by Year’s End if Approved, BioCryst ...
2020-08-19 · Orladeyo is an investigational HAE treatment that works by lowering the levels of bradykinin, an inflammatory molecule that promotes swelling, the overproduction of which characterizes HAE.. Data from the clinical trials APeX-2 (NCT03485911) and APeX-S (NCT03472040, still recruiting) have demonstrated that the medication can significantly reduce …
Angioedemanews.comORLADEYO (berotralstat) - Home | Facebook
ORLADEYO (berotralstat) June 25 ·. This page is a great place to learn about ORLADEYO™ (berotralstat), but have you ever wanted the chance to hear about it live? Join us for an upcoming virtual educational program during which you'll be able to listen to a clinician speaker and a patient ambassador talk about their experiences with ORLADEYO.
Facebook.comorladeyoeventspatient.com - BioCryst
Please check back for program location updates or for questions, please call 1-877-547-5640 or email [email protected]. Click here to visit the ORLADEYO website to get more information prior to joining the program. ABOUT PROGRAMS . This live educational program series on ORLADEYO ® (berotralstat) offers people living within HAE and their …
Orladeyoeventspatient.comBioCryst Announces Preliminary Full Year 2021 ORLADEYO ...
Email Alerts; RSS News Feeds; Share Page; Press Release BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance . January 10, 2022 at 7:00 AM EST. PDF Version —ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY …
Ir.biocryst.comBioCryst to Present New ORLADEYO® (berotralstat) Data at ...
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …
Ir.biocryst.comOrladeyo see strong patient demand - HAE International (HAEi)
2022-01-10 · Fourth Quarter 2021 Orladeyo Launch Dynamics: New patient demand for Orladeyo remains strong and consistent, with a similar number of new patients added in Q4 2021 as in each of the previous three quarters of the year. Patients switching from other prophylactic therapies and acute-only therapy continue to drive the launch. More than half of patients new …
Haei.orgBioCryst Presents New Data Demonstrating Sustained ...
2022-02-24 · ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4 ...
Finance.yahoo.comBioCryst Submits Marketing Authorization Application for ...
2021-03-02 · ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …
Ca.finance.yahoo.comBioCryst Reports Fourth Quarter and Full Year 2021 ...
2021-12-31 · — Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients —
Marketscreener.comBioCryst Announces FDA Approval of ORLADEYO™ (berotralstat ...
2020-12-04 · ORLADEYO™ (berotralstat) capsules ORLADEYO™ (berotralstat) capsules 150 mg—Significant and sustained reduction in HAE attacks— —Oral, once-daily prophylactic option enables HAE patients ...
Finance.yahoo.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| duttonhvac.com | wildwestdomains.com | -2 Years, -93 Days |
| cribagorza.org | nicline.com | -2 Years, -76 Days |
| theskepticalcardiologist.com | wildwestdomains.com | -1 Years, -317 Days |
| modgnews.com | tucows.com | -2 Years, -192 Days |
| inter-col.com | dondominio.com | -2 Years, -233 Days |
| tonyward.net | namecheap.com | -2 Years, -149 Days |
| medyanews.net | ascio.com | -2 Years, -141 Days |
| unisalia.com | namecheap.com | -2 Years, -53 Days |
| dynv6.com | hetzner.com | -2 Years, -16 Days |
| sattarsanitarystores.in | godaddy.com | -1 Years, -317 Days |